Fighting cancers from within: Augmenting tumor immunity with cytokine therapy

Trends in Pharmacological Sciences

Volumn 31, Issue 8, 2010, Pages 356-363

  Pellegrini, Marc ^a   Mak, Tak W ^b   Ohashi, Pamela S ^b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD137 LIGAND; CD20 ANTIGEN; CD8 ANTIGEN; CETUXIMAB; CYTOKINE; DENDRITIC CELL VACCINE; DNA METHYLTRANSFERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELANOMA VACCINE; OX40 LIGAND; PROVENGE; RITUXIMAB; SIPULEUCEL; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL KILLING; CELL TRANSFER; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; DRUG TARGETING; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADJUVANTS, IMMUNOLOGIC; CYTOKINES; HUMANS; IMMUNITY; IMMUNOTHERAPY; NEOPLASMS;

EID: 77955280009     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.05.003     Document Type: Review

References (94)

1. de Visser K.E., Coussens L.M. The inflammatory tumor microenvironment and its impact on cancer development. Contrib. Microbiol. 2006, 13:118-137.
2. Swann J.B., Smyth M.J. Immune surveillance of tumors. J. Clin. Invest 2007, 117:1137-1146.
3. Willimsky G., et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 2008, 205:1687-1700.
4. Koebel C.M., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
5. Finak G., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
6. Parmiani G., et al. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 2007, 178:1975-1979.
7. Ohashi P.S. Negative selection and autoimmunity. Curr. Opin. Immunol. 2003, 15:668-676.
8. Nguyen L.T., et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 2002, 195:423-435.
9. Akira S., et al. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
10. Tesniere A., et al. Immunogenic cancer cell death: a key-lock paradigm. Curr. Opin. Immunol. 2008, 20:504-511.
11. Ghiringhelli F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
12. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
13. Rosenberg S.A., et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8:299-308.
14. Morgan R.A., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
15. Zitvogel L., et al. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8:59-73.
16. Murdoch C., et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
17. Rabinovich G.A., et al. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25:267-296.
18. Pittet M.J. Behavior of immune players in the tumor microenvironment. Curr. Opin. Oncol. 2009, 21:53-59.
19. Krambeck A.E., et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10391-10396.
20. Blank C., Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol. Immunother. 2007, 56:739-745.
21. Mantovani A., et al. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008, 371:771-783.
22. Katz J.B., et al. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 2008, 222:206-221.
23. Weiner L.M., et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
24. Koebel C.M., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
25. Reits E.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 2006, 203:1259-1271.
26. Karpf A.R. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006, 1:116-120.
27. Dunn G.P., et al. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006, 6:836-848.
28. Chan C.J., et al. Can NK cells be a therapeutic target in human cancer?. Eur. J. Immunol. 2008, 38:2964-2968.
29. Peggs K.S., et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 2009, 206:1717-1725.
30. Lin A.E., Mak T.W. The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells. Curr. Opin. Immunol. 2007, 19:665-673.
31. Yoshimura A., et al. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 2007, 7:454-465.
32. Huang G.N., et al. NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science 2008, 319:476-481.
33. Zha Y., et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat. Immunol. 2006, 7:1166-1173.
34. Safford M., et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 2005, 6:472-480.
35. Hedrick S.M. The cunning little vixen: Foxo and the cycle of life and death. Nat. Immunol. 2009, 10:1057-1063.
36. Ringden O., et al. The allogeneic graft-versus-cancer effect. Br. J. Haematol. 2009, 147:614-633.
37. Dranoff G. Targets of protective tumor immunity. Ann. N. Y. Acad. Sci. 2009, 1174:74-80.
38. Harzstark A.L., Small E.J. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc) 2008, 44:271-278.
39. Capitini C.M., et al. Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer. Am. J. Immunol. 2009, 5:65-83.
40. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006, 6:595-601.
41. Zhang H., et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat. Med. 2005, 11:1238-1243.
42. Boyman O., et al. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311:1924-1927.
43. Capitini C.M., et al. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J. Intern. Med. 2009, 266:141-153.
44. Vosshenrich C.A., et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat. Immunol. 2006, 7:1217-1224.
45. Vogt T.K., et al. Novel function for interleukin-7 in dendritic cell development. Blood 2009, 113:3961-3968.
46. Schmutz S., et al. Cutting edge: IL-7 regulates the peripheral pool of adult ROR gamma+ lymphoid tissue inducer cells. J. Immunol. 2009, 183:2217-2221.
47. Satoh-Takayama N., et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J.Exp. Med. 2010, 207:273-280.
48. Dubois S., et al. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002, 17:537-547.
49. Zhao H., et al. Interleukin 15 controls the generation of the restricted T cell receptor repertoire of gamma delta intestinal intraepithelial lymphocytes. Nat. Immunol. 2005, 6:1263-1271.
50. Lee C.C., et al. The regulatory function of umbilical cord blood CD4(+) CD25(+) T cells stimulated with anti-CD3/anti-CD28 and exogenous interleukin (IL)-2 or IL-15. Pediatr. Allergy Immunol. 2009, 20:624-632.
51. Imamichi H., et al. IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3. Eur. J. Immunol. 2008, 38:1621-1630.
52. Ozaki K., et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002, 298:1630-1634.
53. Elsaesser H., et al. IL-21 is required to control chronic viral infection. Science 2009, 324:1569-1572.
54. Frohlich A., et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009, 324:1576-1580.
55. Yi J.S., et al. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009, 324:1572-1576.
56. Zeng R., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 2005, 201:139-148.
57. Liu S., et al. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int. Immunol. 2007, 19:1213-1221.
58. Korn T., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
59. Nurieva R., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
60. Muranski P., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
61. Martin-Orozco N., et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31:787-798.
62. Pellegrini M., et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 2009, 15:528-536.
63. kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 2000, 6:290-297.
64. Li L., et al. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat. Immunol. 2006, 7:1157-1165.
65. Barata J.T., et al. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27kip1. Blood 2001, 98:1524-1531.
66. Li W.Q., et al. IL-7 promotes T cell proliferation through destabilization of p27Kip1. J. Exp. Med. 2006, 203:573-582.
67. Bendle G.M., et al. A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function. PLoS One 2007, 2:e353.
68. Teague R.M., et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 2006, 12:335-341.
69. Lynch D.H., Miller R.E. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J. Exp. Med. 1994, 179:31-42.
70. Gattinoni L., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907-912.
71. Frederiksen K.S., et al. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol. Immunother. 2008, 57:1439-1449.
72. Davis I.D., et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 2007, 13:3630-3636.
73. Tamang D.L., et al. Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. Cytokine 2006, 36:148-159.
74. Stoklasek T.A., et al. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 2006, 177:6072-6080.
75. Epardaud M., et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 2008, 68:2972-2983.
76. Klebanoff C.A., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1969-1974.
77. Roychowdhury S., et al. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res. 2004, 64:8062-8067.
78. Melchionda F., et al. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J. Clin. Invest. 2005, 115:1177-1187.
79. Sportes C., et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 2008, 205:1701-1714.
80. Calzascia T., et al. CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2999-3004.
81. Ruprecht C.R., et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J. Exp. Med. 2005, 201:1793-1803.
82. Ben Ahmed M., et al. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J. Immunol. 2009, 182:6763-6770.
83. Cui Y., et al. Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 2009, 114:3831-3840.
84. Bhave N.S., Carson W.E. Immune modulation with interleukin-21. Ann. N.Y. Acad. Sci. 2009, 1182:39-46.
85. Lucas M., et al. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007, 26:503-517.
86. Brilot F., et al. NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha. J. Clin. Invest. 2007, 117:3316-3329.
87. Eklund J.W., Kuzel T.M. A review of recent findings involving interleukin-2-based cancer therapy. Curr. Opin. Oncol. 2004, 16:542-546.
88. Smith F.O., et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 2008, 14:5610-5618.
89. Dudley M.E., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
90. Wang L.X., et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 2005, 65:10569-10577.
91. Wallen H., et al. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One 2009, 4:e4749.
92. Rosenberg S.A., et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 2006, 29:313-319.
93. Moller P., et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br. J. Cancer. 1998, 77:1907-1916.
94. Dodds M.G., et al. Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunol. Immunother. 2009, 58:843-854.